The CEO of Arrowhead Research is Exercising Options

By Carrie Williams

Yesterday it was reported that the CEO of Arrowhead Research (ARWRResearch Report), Christopher Richard Anzalone, exercised options to buy 49,448 ARWR shares at $2.12 a share, for a total transaction value of $105.1K.

Following Christopher Richard Anzalone’s last ARWR Buy transaction on April 05, 2019, the stock climbed by 5.0%. Following this transaction Christopher Richard Anzalone’s holding in the company was increased by 2.37% to a total of $53.53 million.

See today’s analyst top recommended stocks >>

Based on Arrowhead Research’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $48.15 million and quarterly net profit of $23.9 million. In comparison, last year the company earned revenue of $650.1K and had a GAAP net loss of $14.88 million. ARWR’s market cap is $2.37B and the company has a P/E ratio of 367.50. Currently, Arrowhead Research has an average volume of 2.03M.

Starting in September 2018, ARWR received 27 Buy ratings in a row. Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $28.38, reflecting a 13.6% upside. Four different firms, including B.Riley FBR and Cantor Fitzgerald, currently also have a Buy rating on the stock.

In the last 30 days, insiders have sold $746.4K worth of ARWR shares and purchased $105.1K worth of ARWR shares. The insider sentiment on Arrowhead Research has been negative according to 43 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Christopher Richard Anzalone’s trades have generated a -38.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.